Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ALT |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | 341 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 415.3M |
| IPO Year | 2000 | 2005 |
| Metric | OSPN | ALT |
|---|---|---|
| Price | $10.63 | $3.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $17.67 |
| AVG Volume (30 Days) | 602.4K | ★ 2.9M |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | ★ 28.77 | 25.37 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | $41,000.00 |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $5.54 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.13 | $2.91 |
| 52 Week High | $18.13 | $7.73 |
| Indicator | OSPN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 32.85 |
| Support Level | $10.26 | $2.91 |
| Resistance Level | $11.68 | $4.25 |
| Average True Range (ATR) | 0.33 | 0.23 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 62.07 | 3.65 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.